Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the rate of healing as well as percent of
wounds healed in Type II diabetic patients with chronic foot ulcerations receiving
sitagliptin versus placebo.
The hypothesis for this study is that subjects receiving daily doses of sitagliptin in
combination with their regular antihyperglycemic medications will result in increased healing
rates as well as a greater number of healed wounds as compared to subjects receiving placebo
and their regular antihyperglycemic medications.